Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.
Sally W. Wade, MPH
Advertisement
Articles by Sally W. Wade, MPH
Adherence to newly initiated biologic therapy for rheumatoid arthritis is important for long-term adherence.
Advertisement
Latest Updated Articles
Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive DisorderPublished: July 23rd 2025 | Updated:
- Two-Year Adherence and Costs for Biologic Therapy for Rheumatoid Arthritis
Published: July 12th 2018 | Updated:
- Growth in Use of Lipid-lowering Therapies: Are We Targeting the Right Patients?
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
5
